

### ***Remarks***

Reconsideration of this application is respectfully requested. Based on the above amendment and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

#### ***I. Status of the Claims***

Claims 31-122 are pending in the application, with 31-35, 52, 70, 89, and 106 being the independent claims. No amendments are made to the claims at this time, and no new matter is introduced.

#### ***II. Amendments***

In addition to the previous amendment, filed on July 16, 2007, updating the relationship between the instant application and its parent application (Pat. No. 6,723,549), Applicants have also amended the specification to indicate the sequence identity for the amino acid sequences in Figures 19, 21, 23, and 27. Based on the Examiner's suggestions, both in the Advisory Action and during the telephonic communications of August 8, 2007 and of August 9, 2007 with Applicants' undersigned representative, the additional phrase, "the encoded amino acid sequence (SEQ ID NO: [31, 33, 35, or 37])," has been added in the section of "Brief Description of the Figures" in the specification. Support for this amendment can be found, *inter alia*, in Figures 19 (A and B), 21 (A, B, and C), 23 (A, B, and C) and 27, and SEQ ID NOs: 31, 33, 35 and 37, as originally filed. This change is believed to introduce no new matter, and its entry is respectfully requested.

***III. Objections of the Claims, Drawings, Sequence Compliance, and Specification***

At pages 2-5 of the Advisory Action, the Examiner states that Applicants' amendment and arguments of July 16, 2007, has not been entered, because not all the suggested amendments either to the specification or to the claims have been made.

Solely to expedite prosecution and not in acquiescence to the propriety of the objections, Applicants have provided the appropriate SEQ ID NOs to the amino acid sequences in Figures 19, 21, 23, and 27 under the section of "Brief Description of the Figures" in the specification, as suggested by the Examiner. As presently amended, Figures 19, 21, 23, and 27 show the amino acid sequences of SEQ ID NOs: 31, 33, 35, and 37, respectively.

Accordingly, Applicants respectfully request that the Examiner reconsider and withdraw all outstanding objections and rejections and that the present amendment and the previous amendment, filed on July 16, 2007, be entered.


***Conclusion***

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Advisory Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*for*  *Reg# 55,472*  
Timothy J. Shea, Jr.  
Attorney for Applicants  
Registration No. 41,306

Date: August 16, 2007

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
710175v1